New emerging technologies and the intradermal route: The novel way to immunize against influenza

Vaccine

Volumn 28, Issue SUPPL. 4, 2010, Pages

  Falsey, Ann R ^a  

^a ROCHESTER GENERAL HOSPITAL   (United States)

Author keywords

Acceptability; Enhanced immunogenicity; Influenza virus; Intradermal vaccination

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE;

ARTICLE; DERMIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE PAIN; NEEDLE; PANDEMIC INFLUENZA; PHOBIA; PRIORITY JOURNAL; SEASONAL INFLUENZA; SKIN REDNESS; SKIN SWELLING; TECHNOLOGY; TREATMENT RESPONSE; TUBERCULIN TEST; ADOLESCENT; AGED; CHILD; CLINICAL TRIAL (TOPIC); IMMUNIZATION; INFLUENZA, HUMAN; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES;

ADOLESCENT; AGED; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED;

EID: 77955634466     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.026     Document Type: Article

References (52)

1. Olsen S.J., Ungchusak K., Sovann L., Uyeki T.M., Dowell S.F., Cox N.J., et al. Family clustering of avian influenza A (H5N1). Emerg Infect Dis 2005, 11:1799-1801.
2. Bautista E., Chotpitayasunondh T., et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010, 362:1708-1719. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza.
3. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289:179-186.
4. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., et al. Influenza-associated hospitalizations in the United States. JAMA 2004, 292:1333-1340.
5. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355:31-40.
6. Molinari N.A., Ortega-Sanchez I.R., Messonnier M.L., Thompson W.W., Wortley P.M., Weintraub E., et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007, 25:5086-5096.
7. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58:1-52.
8. Poland G.A., Morse D. Improving the public health: the U.S. recommendation for universal influenza immunization. Vaccine 2010, 28:2799-2800.
9. Michel J.P. Updated vaccine guidelines for aging and aged citizens of Europe. Expert Rev Vaccines 2010, 9:7-10.
10. Stinchfield P.K. Practice-proven interventions to increase vaccination rates and broaden the immunization season. Am J Med 2008, 121:S11-21.
11. Muller D., Szucs T.D. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Infection 2007, 35:308-319.
12. Hollmeyer H.G., Hayden F., Poland G., Buchholz U. Influenza vaccination of health care workers in hospitals-a review of studies on attitudes and predictors. Vaccine 2009, 27:3935-3944.
13. Keeton V.F., Chen A.K. Immunization updates and challenges. Curr Opin Pediatr 2010, 22:234-240.
14. Naleway A.L., Smith W.J., Mullooly J.P. Delivering influenza vaccine to pregnant women. Epidemiol Rev 2006, 28:47-53.
15. Babiuk S., Baca-Estrada M., Babiuk L.A., Ewen C., Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J Control Release 2000, 66:199-214.
16. Nandedkar T.D. Nanovaccines: recent developments in vaccination. J Biosci 2009, 34:995-1003.
17. Combadiere B., Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp Immunol Microbiol Infect Dis 2008, 31:293-315.
18. Nicolas J.F., Guy B., Intradermal epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008, 7:1201-1214.
19. Egemen A., Aksit S., Kurugol Z., Erensoy S., Bilgic A., Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 1998, 16:1511-1515.
20. Halperin W., Weiss W.I., Altman R., Diamond M.A., Black K.J., Iaci A.W., et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am J Public Health 1979, 69:1247-1251.
21. Halsey N.A., Reppert E.J., Margolis H.S., Francis D.P., Fields H.A. Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine 1986, 4:228-232.
22. Toovey S. Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience. Travel Med Infect Dis 2007, 5:327-348.
23. Vien N.C., Feroldi E., Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 2008, 102:294-296.
24. Lang J., Hoa D.Q., Gioi N.V., Vien N.C., Nguyen C.V., Rouyrre N., et al. Immunogenicity and safety of low-dose intradermal rabies vaccination given during an Expanded Programme on immunization session in Viet Nam: results of a comparative randomized trial. Trans R Soc Trop Med Hyg 1999, 93:208-213.
25. Chanchairujira T., Chantaphakul N., Thanwandee T., Ong-Ajyooth L. Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J Med Assoc Thai 2006, 89(Suppl 2):S33-40.
26. Boger W.P., Liu O.C. Subcutaneous and intradermal vaccination with Asian influenza vaccine. J Am Med Assoc 1957, 165:1687-1689.
27. Payler D.K., Skirrow M.B. Letter: Intradermal influenza vaccination. Br Med J 1974, 2:727.
28. Stille W.T., Woolridge R.L., Gundelfinger B.F. Antibody response to intracutaneous and subcutaneous influenza vaccination. J Lab Clin Med 1959, 53:751-754.
29. Masurel N., Laufer J. A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection. J Hyg (Lond) 1984, 92:263-276.
30. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351:2295-2301.
31. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004, 351:2286-2294.
32. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007, 25:659-663.
33. Künzi V., Klap J.M., Seiberling M.K., Herzog C., Hartmann K., Kürsteiner O., et al. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 2009, 27:3561-3567.
34. Kilbourne E.D. Intradermal vaccination against influenza. N Engl J Med 2005, 352:1044-1046.
35. Belshe R.B., Newman F.K., Wilkins K., Graham I.L., Babusis E., Ewell M., et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007, 25:6755-6763.
36. Mikszta J.A., Laurent P.E. Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook. Expert Rev Vaccines 2008, 7:1329-1339.
37. Leroux-Roels I., Vets E., Freese R., Seiberling M., Weber F., Salamand C., et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008, 26:6614-6619.
38. Van Damme P., Oosterhuis-Kafeja F., Van der Wielen M., Almagor Y., Sharon O., Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009, 27:454-459.
39. Beran J., Ambrozaitis A., Laiskonis A., Mickuviene N., Bacart P., Calozet Y., et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009, 7:13.
40. Chiu S.S., Peiris J.S., Chan K.H., Wong W.H., Lau Y.L. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 2007, 119:1076-1082.
41. Sugimura T., Ito Y., Tananari Y., Ozaki Y., Maeno Y., Yamaoka T., et al. Improved antibody responses in infants less than 1 year old using intradermal influenza vaccination. Vaccine 2008, 26:2700-2705.
42. Chiu S.S., Chan K.H., Tu W., Lau Y.L., Peiris J.S. Immunogenicity and safety of intradermal versus intramuscular route of influenza immunization in infants less than 6 months of age: a randomized controlled trial. Vaccine 2009, 27:4834-4839.
43. Goodwin K., Viboud C., Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006, 24:1159-1169.
44. Holland D., Booy R., De Looze F., Eizenberg P., McDonald J., Karrasch J., et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008, 198:650-658.
45. Arnou R., Icardi G., De Decker M., Ambrozaitis A., Kazek M.P., Weber F., et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009, 27:7304-7312.
46. Jo Y.M., Song J.Y., Hwang I.S., Lee J., Oh S.C., Kim J.S., et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. J Med Virol 2009, 81:722-727.
47. Khanlou H., Sanchez S., Babaie M., Chien C., Hamwi G., Ricaurte J.C., et al. The safety and efficacy of dose-sparing intradermal administration of influenza vaccine in human immunodeficiency virus-positive patients. Arch Intern Med 2006, 166:1417.
48. Gelinck L.B., van den Bemt B.J., Marijt W.A., van der Bijl A.E., Visser L.G., Cats H.A., et al. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 2009, 27:2469-2474.
49. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
50. Patel S.M., Atmar R.L., El Sahly H.M., Cate T.R., Keitel W.A. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine 2010, 28:3025-3029.
51. Nicholson K.G., Thompson C.I., Klap J.M., Wood J.M., Batham S., Newman R.W., et al. Safety and immunogenicity of whole-virus, alum-adjuvanted whole virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations. Vaccine 2009, 28:171.
52. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials. Hum Vaccin.[Epub ahead of print 2010 Apr 26].